Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

NCT05113966 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
30
Enrollment
INDUSTRY
Sponsor class

Stopped The Sponsor decided to close enrollment to the study on Feb 14, 2023, in order to reallocate resources to other ongoing trilaciclib clinical trials.

Conditions

Interventions

Sponsor

G1 Therapeutics, Inc.